Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Hematology/Neutropenia

Neutropenia

20

Pipeline Programs↗

15

Active Trials↗

28

Companies Involved↗

Neutropenia is an emerging landscape with 20 programs across 28 companies. The most active players are X4 Pharmaceuticals. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

68/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

X4 Pharmaceuticals

1 program

Pipeline

Programs by Phase

Preclinical11

Neulasta

Amgen

Itraconazole

Sebela Pharmaceuticals Development LLC

Zidovudine

Bp Consulting, Inc

Teicoplanin

Sanofi

Piperacillin-Tazobactam Combination Product

The University of Queensland

Phase 1

No programs

Phase 26

Bevacizumab

Roche

Trifluridine/tipiracil

AbbVie

Efbemalenograstim Alfa

Henan Cancer Hospital

Eravacycline

Tetraphase Pharmaceuticals, Inc

Tripegfilgrastim

Dong-A ST Co., Ltd.

Phase 33

Mavorixafor

X4 Pharmaceuticals

G-CSF

Arog Pharmaceuticals, Inc.

PEG-G-CSF

Sanofi

Approved

No programs

Analysis

Modality Breakdown

65%

Small molecule

13 of 20 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

108

clinical trials

Completed47 · 44%

Unknown status24 · 22%

Terminated15 · 14%

Recruiting8 · 7%

Withdrawn7 · 6%

Not yet recruiting5 · 5%

Other2 · 2%

Clinical Trials

Trial Activity

108 trials

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.

Recruiting·BBeneficência Portuguesa de São Paulo·Approved·NCT06342115·55 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Recruiting·XX4 Pharmaceuticals·Phase 3·NCT06056297·176 enrolled

Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor

Recruiting·—·N/A·NCT07096479·318 enrolled

Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance

Recruiting·—·Phase 4·NCT06293677·30 enrolled

Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection

Recruiting·HHebei Medical University Fourth Hospital·N/A·NCT07434063·200 enrolled

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Recruiting·National Cancer Center, Korea·Phase 2·NCT06135896·98 enrolled

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Recruiting·HHenan Cancer Hospital·Phase 2·NCT07187908·1,076 enrolled

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting·WWest Virginia University·Phase 2·NCT05537896·55 enrolled

The Impact of Neutropenic Precaution Education on Knowledge, Adherence, and Infection Rates in Patients With Cancer: A Pharmacist-Led Intervention

Active, not recruiting·JJordan University of Science and Technology·Preclinical·NCT07690956·300 enrolled

Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy

Active, not recruiting·KKexing Biopharm Co., Ltd.·Phase 3·NCT06711523·250 enrolled

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Not yet recruiting·—·Phase 2·NCT06926751·132 enrolled

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

Not yet recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT07071844·162 enrolled

Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase

Not yet recruiting·GGadjah Mada University·Phase 4·NCT07320534·124 enrolled

Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia

Not yet recruiting·KKing Edward Medical University·Phase 4·NCT06988826·150 enrolled

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06143735·99 enrolled

Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)